Info@mhcombiotic.com
Through extensive research and collaborations with leading institutions, we have developed targeted solutions to combat wound and respiratory infections.
Advancing Antimicrobial Solutions for Critical Infections
Biocompatibility
Discovery
Wound Care – Medical Device
Biofilms are structured microbial communities that form on wound surfaces, delaying healing and increasing infection risk. Over 90% of chronic wounds, including diabetic foot ulcers, involve biofilms, leading to prolonged treatment, higher healthcare costs, and increased risk of amputation. Combiotic™ technology has been developed after screening 18,000+ formulations, demonstrating efficacy in biofilm disruption, infection control, and wound recovery acceleration while minimizing toxicity and antimicrobial resistance.
Respiratory – Therapeutics
Respiratory infections remain a leading cause of global mortality, disproportionately affecting infants, the elderly, and immunocompromised individuals. Combiotic™ technology is being investigated for its broad-spectrum antimicrobial properties, capable of inhibiting biofilm formation, bacterial proliferation, and inflammation. Its ability to mitigate oxidative stress and enhance antimicrobial potency offers potential therapeutic applications in managing drug-resistant respiratory infections.